PharmaJet’s Needle-free intradermal (ID) injection device (“Tropis® ID”) will be evaluated as delivery system for the tuberculin skin test (TST) in a clinical study conducted by REDE-TB. The study ...

PharmaJet, a global leader in needle-free injection technology, today announced that its WHO-prequalified Tropis ID Needle-free Injection System will be used to deliver approximately 1.4 million doses ...

CHICAGO--(BUSINESS WIRE)--Sol-Millennium® Medical Group, manufacturer of medical devices, including syringes for medication delivery and testing, is proud to announce the launch of InsuJet™ ...

GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet ®, the maker of innovative, needle-free injection technology, today announced that its partner, Zydus Cadila, has received the Emergency Use Authorization ...

FlowBeams' needle-free injection technology could prove to be a watershed moment in healthcare and aesthetic dermatology Development of the world’s first affordable laser-based, needle-free injection ...

PharmaJet® to Highlight the Benefits of Intradermal Needle-free Delivery and Expansion into the Self-Injection Pen Market at Upcoming PODD Conference PharmaJet will deliver two presentations on ...

PharmaJet ®, a company focused on improving the performance and outcomes of injectables through needle-free injection technology, announced that its partner, Brazilian Tuberculosis Research Network ...

The MarketWatch News Department was not involved in the creation of this content. -- PharmaJet's Needle-free intradermal (ID) injection device ("Tropis(R) ID") will be evaluated as delivery system for ...